Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
GDRX · against 467 other Healthcare companies of similar size
Ranked #175 of 468 · scores higher than 62% of peers
Bars: peers in each 10-point band of the valuation score44 peers with a valuation score of 60–69, including GDRX · Click a bar to see the companies
Mainly thanks to its free cash flow yield and EBITDA yield, which are stronger than most Healthcare peers.
| Metric | GDRX | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 459 reported | 1.4% | 1.4% | 50% | 30% | |
| EBITDA yieldHigher is better · 471 reported | 7.6% | 4.3% | 69% | 50% | |
| Free cash flow yieldHigher is better · 206 reported | 11.1% | -1.6% | 92% | 20% | |
| Book yieldHigher is better · 463 reported | 54.6% | 40.7% | 65% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 12.9B HKD (≈$1.7B) | 99 | 83 | |
| 1 | 89.9B JPY (≈$611M) | 99 | 68 | |
| 1 | 226.3B JPY (≈$1.5B) | 99 | 77 | |
| 1 | 40.2B MXN (≈$2.2B) | 99 | 71 | |
| 170 | 2.4B USD | 68 | 64 | |
| 170 | 1.4B USD | 68 | 42 | |
| 175 | 6.0B CNY (≈$841M) | 67 | 50 | |
| 175 | 2.7B CAD (≈$2.0B) | 67 | 54 | |
| 175 | 1.2B USD | 67 | 39 | |
| 178 | 15.0B CNY (≈$2.1B) | 66 | 55 | |
| 178 | 1.9B USD | 66 | 38 | |
| 180 | 10.2B CNY (≈$1.4B) | 65 | 55 | |
| 180 | 51.2B INR (≈$614M) | 65 | 63 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score